ended5월 8일· 1 sources
[바이오사 리포트] 에이비엘, 릴리 딜로 현금 보강…후속 LO 시험대
Why it matters
ABL Bio's strategic deal with Eli Lilly for its Grabody-B platform has significantly bolstered its cash reserves, providing a stable financial foundation for intensive R&D. This transition highlights the commercial scalability of their BBB shuttle technology and paves the way for upcoming Phase 3 clinical trials and high-growth bispecific ADC development.
1
Sources
+0
24h
—
Growth
135d
Active
ABL BioGrabody-BEli LillyLicense OutBispecific AntibodyADC